Avac Event

Save HIV Funding Rally

On Wednesday, October 21 join the Save HIV Funding campaign at IDWeek 2026 for a rally calling for the restoration and protection of federal HIV funding.

The #CutsKill Quilt art installation returns to IDWeek as a powerful visual reminder of the human impact of HIV funding cuts and the urgent need to protect HIV prevention, treatment, care and research.

Emceed by AVAC’s Mitchell Warren, the rally will feature Jeanne Marrazzo, IDSA, Anna Person, HIVMA, Ronald Johnson, U.S. People Living with HIV Caucus, Nada Fadul, HIVMA, Benjamin Brooks, Whitman-Walker Health and Jeremiah Johnson, PrEP4All / Save HIV Funding.

The event is open to all attending IDWeek.

Funding shifts leave HIV community-based organizations with less say

Shock waves rippled through the network of U.S. HIV/AIDS service organizations when the Centers for Disease Control and Prevention (CDC) announced in July that it would no longer directly fund nearly 100 community-based organizations (CBOs), as it had for many years, instead shifting funding to state and local health departments. Mitchell Warren, AVAC’s Executive Director, says that the shift away from involving communities is part of a larger effort to conceal PEPFAR’s activities and progress from outside observers and advocates. “The U.S. government has dramatically changed how it treats civil society, which has been tumultuous and leaves us with a lot of confusion.”

HIV advocates sound alarm as NIH hits ‘pause’ on new HIV clinical trials

The National Institutes of Health (NIH) notified four major research networks that they should “pause” new clinical studies that had not yet enrolled participants and that could not be completed by November 30, 2027, when their current funding expires. As AVAC’s Executive Director Mitchell Warren says, “This may be one of the most shortsighted, scientifically absurd and ideologically wrong decisions, and there have been a lot of those in the last 20 months.”

Global Health Watch: NIH Orders Pause on HIV Trials, Zimbabwe + Zambia Health MoUs, WHO + Global Fund leadership, Foreign Assistance Funds

Issue 89

The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be complete by November 30, 2027, when their current funding is set to expire.” This potentially devastating development comes as new questions emerge about how billions in US foreign assistance funding were spent, and details on the impacts of an end of US health assistance to Zimbabwe emerge. Also, a new candidate for WHO leadership and growing civil society calls to protect UNAIDS.

NIH Orders Pause on New HIV Clinical Trials Amid Funding Delays 

The National Institutes of Health (NIH) instructed leaders of its four HIV clinical trials networks to temporarily pause launching new studies that have not yet begun enrolling participants and would extend beyond November 30, 2027 (when funding expires). As The New York Times reports, this comes amid continued delays in releasing Notices of Funding Opportunities (NOFOs) to renew the networks and the Centers for AIDS Research (CFARs) for the next seven years, threatening research infrastructure built over decades and potentially disrupting clinical trials and services for participants. In response, AVAC, along with allies PrEP4All, HIVMA, TAG, and AIDS Action Baltimore as part of the Save HIV Funding Campaign are inviting sign-ons to a letter to Congress demanding that the US Department of Health and Human Services (HHS) authorize the long overdue funding announcements. Organizations can sign-on by October 15. 

IMPLICATIONS: The affected clinical trial networks include the Advancing Clinical Therapeutics Globally for HIV (ACTG), HIV Prevention Trials Network (HPTN), HIV Vaccine Trials Network (HVTN), and the International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT). The delayed renewal of the networks and the directive to hold off on launching new studies create uncertainty for the research pipeline, potentially delaying scientific advances, disrupting services for trial participants and weakening infrastructure built over decades. These networks have yielded critical advancements for HIV treatment and prevention and are important catalysts for tuberculosis treatment and prevention research, and for other emerging infectious diseases. Simultaneously, the proposed NIAID reorganization raises questions about the future of centralized clinical research oversight and support. As AVAC shared with the NIAID Council and the AIDS Research Advisory Committee (ARAC) at their meeting September 27, “Collectively, these programs have saved millions of lives over the last several decades and advanced some of the most important scientific discoveries and implementation science advances. Delays in the release of the NOFOs are forcing clinical trial sites to prepare for lapses in funding that could harm study participants, halt promising clinical trials, and erode the scientific workforce and infrastructure that has taken decades to develop.” In sum, the continued attacks on the HIV research infrastructure could reshape the trajectory of research for years to come.

READ:

US Health Assistance Ends in Zimbabwe as Zambia Signs New Agreement 

The US Department of State was said to begin implementing its America First Global Health Strategy across 35+ partner countries on October 1, the start of the US fiscal year. But this is all evolving differently across countries. In Zimbabwe, US bilateral health assistance ended September 30 after the two countries failed to reach an agreement. Health GAP details the disagreements, which include sharing health data and biological specimens, but more importantly, major reductions in US funding and co-financing requirements that would have required Zimbabwe to increase its contributions by 290% in the first year. It proposes several next steps to avert the crisis. Health Policy Watch reports that “researchers project that there could be over 75,000 new HIV infections in Zimbabwe within a year ‘as a consequence of full PEPFAR withdrawal and no additional government or international support’.” 

In contrast, the US and Zambia signed a five-year, $2.49 billion health agreement yesterday, following months of negotiations. Zambia reports that requirements to share patient-level health data and biological specimens were removed, while negotiations over critical minerals were separated from the health agreement. Meanwhile, South Africa is preparing for the phaseout of PEPFAR support by March 2027, raising concerns about the future of community-based HIV prevention and treatment services. 

IMPLICATIONS: The withdrawal of US health assistance in Zimbabwe could dismantle decades of progress against HIV, TB and malaria, with consequences beyond the immediate term. Health GAP warns that the crisis could disrupt Zimbabwe’s introduction of injectable lenacapavir for HIV PrEP, jeopardizing access to one of the most important recent advances in HIV prevention. The implications are particularly alarming because these are interconnected programs: disruptions to community health workers, laboratories, supply chains and service delivery can undermine responses to all three diseases simultaneously. 

READ:

Foreign Assistance Funds Committed as Questions Over Spending Persist 

The US 2026 fiscal year ended on September 30, and the picture is becoming slightly clearer on how billions of dollars of Congressionally-appropriated global health funding was actually spent. According to Devex and in court filings, the US Department of State committed more than $4 billion in foreign assistance funding just before the end of the fiscal year, preventing much of that money from expiring. A new filing in the Global Health Council and AVAC court cases shows that only $18,919 in Global Health Programs funding for which the State Department was responsible expired without being committed. However, the filing also identifies funds committed to covering the costs of closing out USAID, rather than supporting health and development programs as Congress had intended.  

IMPLICATIONS: This adds to concerns raised last week about the transfer of $2.5 billion originally intended for global health and development assistance into an alternative or ‘miscellaneous’ account. While the government appears to have met much of the deadline for committing funds, questions remain about where the money is going, whether it is being used as Congress intended and when it will actually reach programs and communities. As AVAC’s Mitchell Warren summarized last week, “the issue extends beyond foreign assistance or the HIV response; it is fundamentally about Congress’s constitutional power of the purse.” 

READ: 

WHO and Global Fund Leadership Updates

Last week, leadership candidates for the Global Fund to Fight AIDS, Tuberculosis and Malaria, and WHO were announced. This week, China confirmed its nomination for WHO Director-General, expanding the known candidates to seven and raising questions about geopolitical influence as the US withdraws from the organization. On his Global Health Insights Substack, former WHO Adviser Peter Singer published a scorecard examining how specifically candidates have articulated plans to deliver measurable results and protect WHO’s scientific independence. And in Lights. Camera. Equity!, former Global Fund Board member Jirair Ratevosian called for greater public engagement in the Global Fund’s selection process. He reported that the Fund confirmed it has no plans for a public candidate forum, with engagement instead taking place through Board constituencies. 

IMPLICATIONS: These developments raise questions about transparency and accountability in choosing the next generation of global health leadership. These new leaders will face immediate decisions that will shape how these institutions define their roles in an evolving architecture. WHO is already reducing its staff significantly after the US refused to support it, and the Global Fund is facing difficult decisions about where and how to invest its smaller Grant Cycle 8 budget. 

READ:

Civil Society Calls for Protecting UNAIDS

Ahead of the October 26 UNAIDS Programme Coordinating Board (PCB) meeting, more than 225 civil society organizations signed an open letter urging members of the PCB to protect the Joint Programme from being dismantled through proposed funding, staffing and operational cuts. Advocates warn that proposals to reduce UNAIDS to a $30 million budget and just 34 staff could undermine its ability to coordinate the global HIV response, defend human rights and ensure meaningful community leadership and accountability. 

IMPLICATIONS: The upcoming UNAIDS PCB meeting will be a defining moment in determining the Joint Programme’s essential functions and whether and how reform can preserve UNAIDS’ leadership, accountability and community engagement.

READ:

What We’re Reading

Resources

HIV Prevention Pipeline: Products to Watch

From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.

An interactive version of this graphic is available.

ARV-Based and Multipurpose Prevention Technology R&D Pipeline

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Click here for a view of all large-scale prevention trials.

At A Glance: The MPT R&D Pipeline

This graphic shows the status of products in development.

Avac Event

Aftershocks Roundtable: How do we rebuild our HIV and public health infrastructure?

On October 28, TCA and IAPAC’s Dr. José M. Zuniga – author of the new book “Aftershocks: Trump 2.0, Public Health, and Our Better Angels” – hosted a dynamic panel to discuss the profound disruption of public health systems over the past almost two years and the urgent need for a coordinated movement to defend and ultimately rebuild them.

“Public health has always been about more than controlling disease,” says Dr. Zuniga. “It is a collective promise that where people live, who they are, whom they love, or how much they earn will not determine whether they can live healthy and dignified lives. That promise is being tested. Our response must be organized, courageous, and ambitious enough not merely to recover what has been lost, but to build what should have existed all along.”

Speakers:

  • Dr. José M. Zuniga, Fast-Track Health, “Aftershocks” author
  • Definate Nhamo, Pangaea Zimbabwe
  • Harold Phillips, NMAC
  • Dr. Shannon Hader, American University School of International Service
  • Tian Johnson, African Alliance

Recording / Transcript

AVAC’s Remarks to the NIAID Council and the ARAC on the proposed NIAID reorganization

AVAC delivered a public comment for the record at the NIAID Council meeting raising concerns about the proposed NIAID reorganization and its potential impact on HIV research, including the elimination of the Division of Clinical Research, disruption to global research and community engagement, and delays in funding for HIV Clinical Trials Networks and Centers for AIDS Research. AVAC urged NIH to withdraw the proposal, provide greater transparency and meaningful opportunities for community input, and immediately release the delayed funding opportunities.

Artificial Intelligence in the HIV response: All the good stuff from AIDS2026

An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the potential of AI to support HIV testing and prevention, including PrEP, and improve linkages to care and services, particularly in sub-Saharan Africa. “AI is becoming a new front door to HIV services,” he writes, but the analysis also shows that while most of the research was focused on feasibility and pilot implementation of AI, a significant evidence gap around health outcomes, as well as privacy, community engagement, and governance remains. He concludes that: AI is working, but trust is what makes or breaks the product; specialized tools beat generics; human-in-the-loop is becoming standard; the field needs to move from pilots to proof of outcomes; and scale depends on systems, not just models.